Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
Autor: | Chris M.G. Thomas, María Moreno, Silvia von Mensdorff-Pouilly, Fred C.G.J. Sweep, René H.M. Verheijen, Leon F.A.G. Massuger, Angèle L.M. Oei |
---|---|
Přispěvatelé: | Obstetrics and gynaecology, CCA - Disease profiling |
Rok vydání: | 2008 |
Předmět: |
Adult
Cancer Research medicine.medical_specialty medicine.medical_treatment Aetiology screening and detection [ONCOL 5] Immunoglobulin E Gastroenterology Disease-Free Survival law.invention Randomized controlled trial Translational research [ONCOL 3] law Internal medicine medicine Humans Yttrium Radioisotopes skin and connective tissue diseases neoplasms MUC1 Molecular diagnosis prognosis and monitoring [UMCN 1.2] Aged Neoplasm Staging Ovarian Neoplasms Hereditary cancer and cancer-related syndromes [ONCOL 1] biology Endocrinology and reproduction [UMCN 5.2] business.industry Immunotoxins Standard treatment Hormonal regulation [IGMD 6] Mucin-1 Antibodies Monoclonal Cancer Immunotherapy gene therapy and transplantation [UMCN 1.4] Immunotherapy Middle Aged medicine.disease Clinical trial Oncology Immunoglobulin G Immunology biology.protein Female Antibody business |
Zdroj: | International Journal of Cancer, 123, 1848-53 International Journal of Cancer, 123, 8, pp. 1848-53 Oei, A L, Moreno, M, Verheijen, R H M, Sweep, F C, Thomas, C M, Massuger, L F & von Mensdorff-Pouilly, S 2008, ' Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer ', International Journal of Cancer, vol. 123, no. 8, pp. 1848-1853 . https://doi.org/10.1002/ijc.23725 International Journal of Cancer, 123(8), 1848-1853. Wiley-Liss Inc. |
ISSN: | 1097-0215 0020-7136 |
Popis: | Contains fulltext : 69735.pdf (Publisher’s version ) (Closed access) We investigated whether epithelial ovarian cancer patients participating in a randomized phase III trial comparing single intraperitoneal (IP) administration of yttrium-90-labeled murine HMFG1 ((90)Y-muHMFG1) plus standard treatment (AT) vs. standard treatment (ST) alone developed IgG ab to MUC1 that had an impact on disease outcome. Serial serum samples from 208 patients in the AT and 199 patients in the ST arm were tested for IgG ab to MUC1 (anti-MUC1 IgG). Anti-MUC1 IgG at weeks 4, 8 and 12 ranked higher in the AT than in the ST arm (p < 0.001). The median (range) area under the curve (AUC) of anti-MUC1 IgG for weeks 1 to 12 was 5.53 (1.51-39.51) and 3.92 (1.17-68.74) for the AT and ST arm, respectively (p < 0.001). An anti-MUC1 IgG AUC > 13 was associated with a benefit in overall survival (OS) and disease-free survival (DFS) in the AT arm in univariate (p = 0.043 and 0.036, respectively), but not in multivariate analysis (Cox proportional hazards regression model). Kaplan-Meier analysis showed a benefit in OS and DFS in patients with an anti-MUC1 IgG AUC > 13 in the AT arm (p = 0.043 and 0.036, respectively), but not in the ST arm. A single IP injection with muHMFG1 did not lead to a survival benefit in the randomized trial, but it induced ab to MUC1 that were associated with an improved disease outcome in patients with highest levels of anti-MUC1 IgG. Immunotherapy against MUC1 could be effective in the treatment of epithelial ovarian cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |